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background:  Exosomes secreted by cardiosphere-derived cells (CDC-XO) mediate the salient benefits of CDCs, which include 
cardioprotection and regeneration after myocardial infarction (MI; Ibrahim et al., Stem Cell Reports 2014). We tested whether incubation 
with CDC-XO might be able to impart therapeutic potency on a cell type that is normally inert (dermal fibroblasts [DFs]).
Methods:  We compared control DFs and CDC-XO-primed DFs at a molecular level and in terms of their abilities to improve myocardial 
structure and function after transplantation into a chronic rat model of MI.
results:  CDC-XO were isolated from media conditioned for 3 days by human cardiospheres. Identity was confirmed by FACS and western 
blot analyses revealing expression of tetraspanins CD63, CD9 and CD81, and by microRNA profiling. Confocal microscopy revealed that 
fluorescently-labeled CDC-XO were internalized within hours by recipient DFs. CDC-XO primed DFs altered the surface phenotype (e.g., 
FSP1 [-33% vs. baseline, p=0.005] and DDR2 [-37%, p=0.01]) and miRNA signature of the secreted exosomes (e.g., miR 223-3p: 110-fold 
increase versus untreated DF exosomes, p=0.01; miR 9-5p: 60-fold increase, p=0.01). CDC-XO-primed DFs enhanced secretion of SDF-1 
and VEGF (p<0.01), increased tube formation by co-cultured human vein endothelial cells (p<0.001), and inhibited neonatal cardiomyocyte 
apoptosis (p=0.013). To test functional efficacy, DFs were incubated with CDC-XO for 24 hours then washed extensively. Primed DFs 
increased ejection fraction (p<0.01) and decreased scar mass (p<0.01), one month post-injection. Immunohistochemistry also revealed 
increased vessel density in animals injected with CDC-XO-primed DFs (p=0.029).
conclusion:  Transient incubation with CDC-XO can convert inert DFs into molecularly-distinct cells with remarkable bioactivity both in 
vitro (angiogenic, cardioprotective) and in vivo (improved function, decreased scar post-MI). The surprising ability of CDC-XO to confer 
therapeutic efficacy on inert DFs while changing their molecular signature identifies a novel amplification mechanism for exosome-
mediated benefits.
